Is Atara Biotherapeutics Inc (ATRA) undervalued? · rev $128.9M
Atara Biotherapeutics Inc (ATRA) is a biotechnology company listed on NASDAQ.
This page asks whether Atara Biotherapeutics Inc (ATRA) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported ATRA revenue for 2024-12-31 was $128.9M. Net income was -$85.4M. Revenue was up 1404.0% from 2023-12-31 to 2024-12-31. ATRA currently screens at market cap $87.1M.
ATRA currently screens at market cap $87.1M. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new ATRA 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare ATRA to the stock page model before you treat a low multiple as a gift.
Not investment advice.